Search

Your search keyword '"Zomas, Athanasios"' showing total 206 results
Start Over Author "Zomas, Athanasios"
206 results on '"Zomas, Athanasios"'

1. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Author

Borchmann, Peter, Ferdinandus, Justin, Schneider, Gundolf, Moccia, Alden, Greil, Richard, Hertzberg, Mark, Schaub, Valdete, Hüttmann, Andreas, Keil, Felix, Dierlamm, Judith, Hänel, Mathias, Novak, Urban, Meissner, Julia, Zimmermann, Andreas, Mathas, Stephan, Zijlstra, Josée M, Fosså, Alexander, Viardot, Andreas, Hertenstein, Bernd, Martin, Sonja, Giri, Pratyush, Scholl, Sebastian, Topp, Max S, Jung, Wolfram, Vucinic, Vladan, Beck, Hans-Joachim, Kerkhoff, Andrea, Unger, Benjamin, Rank, Andreas, Schroers, Roland, zum Büschenfelde, Christian Meyer, de Wit, Maike, Trautmann-Grill, Karolin, Kamper, Peter, Molin, Daniel, Kreissl, Stefanie, Kaul, Helen, von Tresckow, Bastian, Borchmann, Sven, Behringer, Karolin, Fuchs, Michael, Rosenwald, Andreas, Klapper, Wolfram, Eich, Hans-Theodor, Baues, Christian, Zomas, Athanasios, Hallek, Michael, Dietlein, Markus, Kobe, Carsten, and Diehl, Volker

Published
2024
Full Text
View/download PDF

2. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Author

Terpos, Evangelos, Ramasamy, Karthik, Maouche, Nadjoua, Minarik, Jiri, Ntanasis-Stathopoulos, Ioannis, Katodritou, Eirini, Jenner, Matthew W., Plonkova, Hana, Gavriatopoulou, Maria, Vallance, Grant D., Pika, Tomas, Kotsopoulou, Maria, Kothari, Jaimal, Jelinek, Tomas, Kastritis, Efstathios, Aitchison, Robin, Dimopoulos, Meletios A., Zomas, Athanasios, and Hajek, Roman

Published
2020
Full Text
View/download PDF

3. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Author

Chalid, Assaf, primary, Illidge, Timothy, additional, Waser, Nathalie, additional, He, Mary, additional, Li, Tina, additional, Zomas, Athanasios, additional, Bentennakhil, Nawal, additional, Little, Meredith, additional, Ortiz-Romero, Pablo L., additional, Pimpinelli, Nicola, additional, Dalal, Mehul, additional, and Bagot, Martine, additional

Published
2023
Full Text
View/download PDF

4. A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom.

Author

Assaf, Chalid, Illidge, Timothy M., Waser, Nathalie, He, Mary, Li, Tina, Zomas, Athanasios, Bent-Ennakhil, Nawal, Little, Meredith, Ortiz-Romero, Pablo L., Pimpinelli, Nicola, Dalal, Mehul, and Bagot, Martine

Subjects
EVALUATION of medical care, SCIENTIFIC observation, CONFIDENCE intervals, MYCOSIS fungoides, CANCER chemotherapy, RETROSPECTIVE studies, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, RADIOTHERAPY, PROGRESSION-free survival, OVERALL survival, LONGITUDINAL method
Abstract

Simple Summary: Here, we report real-world treatment patterns and the overall survival of 104 patients with relapsing/refractory (R/R) MF who had received first-line therapy between 1984 and 2016. Our study found that second- and third-line therapies for R/RMF were heterogeneous, including systemic therapies, radiotherapy and topical therapies. More than two-thirds of patients at second- and third-line treatment received chemotherapy, and we observed that the median overall survival was longer with non-chemotherapy (not reached) vs. chemotherapy (6.5 years) treatment, suggesting that non-chemotherapy options may be more beneficial to patients. (1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lymphoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes from the subpopulation with R/R MF. (2) Methods: This observational, retrospective, cohort study analyzed patient records (1984–2016) from 27 clinical sites in Europe. Outcomes included treatments received, response to first-, second- and third-line treatment, overall survival (OS) and progression-free survival (PFS). (3) Results: Of 104 patients with MF, 100 received second-line and 61 received third-line therapy. The median (range) times from the start of first-line therapy to the first R/R MF and from the first to the second R/R MF were 11.2 (0.3–166.5) and 13.5 (0.0–174.6) months, respectively. Second-and third-line treatment options varied and comprised systemic therapies (85% and 79% of patients, respectively), radiotherapy (32% and 34%, respectively) and topical therapies (48% and 36%, respectively). The median (95% confidence interval [CI]) OS from the diagnosis of the first R/R MF was 11.5 (6.5–not reached [NR]) years and was higher with non-chemotherapy (NR) versus chemotherapy (6.5 years); the estimated median PFS (95% CI) from the time of the first R/R MF was 1.3 (1.0–2.1) years. (4) Conclusions: High rates of R/R disease were observed after second- and third-line treatments in this real-world cohort, with longer median OS in patients receiving non-chemotherapy treatment versus chemotherapy. Following the standard management of MF and using recently approved targeted therapies can help improve patient outcomes in advanced-stage MF. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

5. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies

Author

Zagouri, Flora, Kastritis, Efstathios, Zomas, Athanasios, Terpos, Evangelos, Katodritou, Eirini, Symeonidis, Argiris, Delimpasi, Sosana, Pouli, Anastasia, Vassilakopoulos, Theodoros P., Michalis, Eurydiki, Giannouli, Stavroula, Kartasis, Zafiris, Christoforidou, Anna, Kokoviadou, Kiriaki, Hatzimichael, Eleftheria, Gika, Dimitra, Megalakaki, Catherine, Papaioannou, Maria, Kyrtsonis, Marie‐Christine, Konstantopoulos, Kostas, and Dimopoulos, Meletios A.

Published
2017
Full Text
View/download PDF

7. Prognostication of the High-Risk WM Patient

Author

Kastritis, Efstathios, Gavriatopoulou, Maria, Kyrtsonis, Marie-Christine, Michael, Michael, Hadjiharissi, Evdoxia, Symeonidis, Argiris, Michalis, Eurydiki, Repoussis, Panagiotis, Tsatalas, Konstantinos, Sioni, Anastasia, Kartasis, Zafiris, Stefanoudaki, Ekaterini, Voulgarelis, Michael, Delimpasi, Sosana, Gika, Dimitra, Vervesou, Elissavet, Konstantopoulos, Konstantinos, Kokkini, Garyfalia, Zomas, Athanasios, Roussou, Paraskevi, Anagnostopoulos, Nikolaos, Economopoulos, Theofanis, Terpos, Evangelos, Zervas, Konstantinos, and Dimopoulos, Meletios A.

Published
2011
Full Text
View/download PDF

8. Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries

Author

Assaf, Chalid, primary, Waser, Nathalie, additional, Bagot, Martine, additional, He, Mary, additional, Li, Tina, additional, Dalal, Mehul, additional, Gavini, Francois, additional, Trinchese, Fabrizio, additional, Zomas, Athanasios, additional, Little, Meredith, additional, Pimpinelli, Nicola, additional, Ortiz-Romero, Pablo L., additional, and Illidge, Timothy M., additional

Published
2021
Full Text
View/download PDF

9. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

Author

Kastritis, Efstathios, Kyrtsonis, Marie-Christine, Hadjiharissi, Evdoxia, Symeonidis, Argyris, Michalis, Evridiki, Repoussis, Panagiotis, Tsatalas, Constantinos, Michael, Michael, Sioni, Anastasia, Kartasis, Zafiris, Stefanoudaki, Ekaterini, Voulgarelis, Michail, Delimpasi, Sossana, Gavriatopoulou, Maria, Koulieris, Efstathios, Gika, Dimitra, Zomas, Athanasios, Roussou, Paraskevi, Anagnostopoulos, Nikolaos, Economopoulos, Theophanis, Terpos, Evangelos, Zervas, Konstantinos, and Dimopoulos, Meletios A.

Published
2010
Full Text
View/download PDF

10. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis

Author

Plattel, Wouter J., primary, Bergamasco, Aurore, additional, Trinchese, Fabrizio, additional, Gavini, François, additional, Bent-Ennakhil, Nawal, additional, Zomas, Athanasios, additional, Castillon, Genaro, additional, Arredondo-Bisono, Teigna, additional, Cristarella, Tiffany, additional, Moride, Yola, additional, and von Tresckow, Bastian, additional

Published
2021
Full Text
View/download PDF

12. Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the ‘Use Via Early Access to Ixazomib’ (UVEA-IXA) Study

Author

Ludwig, Heinz, Terpos, Evangelos, Mateos, María-Victoria, Boccadoro, Mario, Kishore, Bhuvan, Ramasamy, Karthik, Fernandez, Sylvie, Ferri, Fabio, Bent-Ennakhil, Nawal, Zomas, Athanasios, Gavini, François, and Hajek, Roman

Published
2020
Full Text
View/download PDF

14. No significant improvement in the outcome of patients with Waldenströmʼs macroglobulinemia treated over the last 25 years

Author

Kastritis, Efstathios, Kyrtsonis, Marie-Christine, Hatjiharissi, Evdoxia, Symeonidis, Argiris, Michalis, Eurydiki, Repoussis, Panagiotis, Tsatalas, Konstantinos, Michael, Michael, Sioni, Anastasia, Kartasis, Zafiris, Stefanoudaki, Ekaterini, Voulgarelis, Michael, Delimpasi, Sosana, Gavriatopoulou, Maria, Koulieris, Efstathios, Gika, Dimitra, Vervesou, Elissavet, Konstantopoulos, Konstantinos, Kokkini, Garyfalia, Zomas, Athanasios, Roussou, Paraskevi, Anagnostopoulos, Nikolaos, Economopoulos, Theofanis, Terpos, Evangelos, Zervas, Konstantinos, and Dimopoulos, Meletios A.

Published
2011
Full Text
View/download PDF

15. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

Author

Terpos, Evangelos, Katodritou, Eirini, Roussou, Maria, Pouli, Anastasia, Michalis, Eurydiki, Delimpasi, Sosana, Parcharidou, Agapi, Kartasis, Zafiris, Zomas, Athanasios, Symeonidis, Argiris, Viniou, Nora-Athina, Anagnostopoulos, Nikolaos, Economopoulos, Theofanis, Zervas, Konstantinos, and Dimopoulos, Meletios A.

Published
2010
Full Text
View/download PDF

20. Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Author

Bagot, Martine, primary, Illidge, Timothy, additional, Pimpinelli, Nicola, additional, Dalal, Mehul, additional, Zomas, Athanasios, additional, Assaf, Chalid, additional, Waser, Nathalie, additional, He, Zhouqin, additional, Li, Tina, additional, Sambrook, Robert, additional, Trinchese, Fabrizio, additional, Little, Meredith, additional, Bent-Ennakhil, Nawal, additional, and Ortiz-Romero, Pablo L., additional

Published
2019
Full Text
View/download PDF

21. Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey

Author

Merz, Maximilian, primary, Vande Broek, Isabelle, additional, Pérez, Manuel, additional, Kolb, Brigitte, additional, Symeonidis, Argiris, additional, Nikolousis, Emmanouil, additional, Zomas, Athanasios, additional, Gonzalez, Francisco, additional, Kellermann, Lenka, additional, and Goldschmidt, Hartmut, additional

Published
2019
Full Text
View/download PDF

27. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.

Author

Kaloyannidis, Panayotis, Hertzberg, Mark, Webb, Kate, Zomas, Athanasios, Schrover, Rudolf, Hurst, Michael, Jacob, Ian, Nikoglou, Thalia, and Connors, Joseph M.

Subjects
STEM cell transplantation, HODGKIN'S disease, PROGRESSION-free survival, WASTE salvage, PORTFOLIO management (Investments)
Abstract

Summary: Brentuximab vedotin (BV) is the first approved novel agent for salvage treatment of relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation (ASCT). In this study, a literature‐based analysis was undertaken to assess, via an indirect treatment comparison, the comparative efficacy of BV to salvage chemotherapy as treatment for R/R cHL patients following ASCT. This comparative effectiveness research was undertaken to support a reimbursement submission for BV to the Australian Pharmaceutical Benefits Advisory Committee. Retrospective analysis of individual patient data from four data sources demonstrated that the use of BV as first salvage treatment in cHL patients relapsing or progressing post‐ASCT achieved improvements in both clinical response and overall survival. More specifically, BV was associated with an incremental improvement of 22% in overall response rate compared to salvage chemotherapy. Five‐year overall survival and progression‐free survival rates were 92·2% [95% confidence interval (CI): 85·5–99·3%] and 32·2% (95% CI: 19·1–54·6%) respectively for BV, compared to 30·5% (95% CI: 22·2–42·0%) and 3·2% (95% CI: 1·1–8·9%) respectively for salvage chemotherapy. The encouraging results from this conservative analysis have the potential to support informed clinical management and funding decisions for the first salvage of cHL patients demonstrating recurrence after ASCT. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

28. Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Author

Zomas, Athanasios Terpos, Evangelos Katodritou, Eirini and Symeonidis, Argiris Delimpasi, Sosana Pouli, Anastasia and Vassilakopoulos, Theodoros P. Michalis, Eurydiki Giannouli, Stavroula Kartasis, Zafiris Christoforidou, Anna Kokoviadou, Kiriaki Hatzimichael, Eleftheria Gika, Dimitra Megalakaki, Catherine Papaioannou, Maria Kyrtsonis, Marie-Christine and Konstantopoulos, Kostas Dimopoulos, Meletios A. Kastritis, Efstathios

Published
2014

29. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma

Author

Kastritis, Efstathios, primary, Terpos, Evangelos, additional, Roussou, Maria, additional, Gavriatopoulou, Maria, additional, Migkou, Magdalini, additional, Eleutherakis-Papaiakovou, Evangelos, additional, Fotiou, Despoina, additional, Ziogas, Dimitrios, additional, Panagiotidis, Ioannis, additional, Kafantari, Eftychia, additional, Giannouli, Stavroula, additional, Zomas, Athanasios, additional, Konstantopoulos, Konstantinos, additional, and Dimopoulos, Meletios A., additional

Published
2016
Full Text
View/download PDF

31. Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma

Author

Kastritis, Efstathios, primary, Terpos, Evangelos, additional, Gavriatopoulou, Maria, additional, Migkou, Magdalini, additional, Eleutherakis-Papaiakovou, Evangelos, additional, Ziogas, Dimitrios, additional, Panagiotidis, Ioannis, additional, Fotiou, Despoina, additional, Gika, Dimitra, additional, Kalapanida, Despoina, additional, Kafantari, Eftychia, additional, Roussou, Maria, additional, Zagouri, Flora, additional, Giannouli, Stavroula, additional, Zomas, Athanasios, additional, Konstantopoulos, Kostas, additional, and Dimopoulos, Meletios A., additional

Published
2015
Full Text
View/download PDF

32. No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years

Author

Kastritis, Efstathios Kyrtsonis, Marie-Christine Hatjiharissi, Evdoxia Symeonidis, Argiris Michalis, Eurydiki Repoussis, Panagiotis Tsatalas, Konstantinos Michael, Michael Sioni, Anastasia Kartasis, Zafiris Stefanoudaki, Ekaterini and Voulgarelis, Michael Delimpasi, Sosana Gavriatopoulou, Maria and Koulieris, Efstathios Gika, Dimitra Vervesou, Elissavet and Konstantopoulos, Konstantinos Kokkini, Garyfalia Zomas, Athanasios Roussou, Paraskevi Anagnostopoulos, Nikolaos and Economopoulos, Theofanis Terpos, Evangelos Zervas, Konstantinos and Dimopoulos, Meletios A. Greek Myeloma Study Grp

Abstract

The treatment of Waldenstrom’s macroglobulinemia (WM) has changed over the last decades, mainly because of the introduction of nucleoside analogues and of rituximab while novel agents such as bortezomib have been recently introduced. We performed an analysis to investigate whether the outcome of patients with WM has improved over the last years, compared to that of patients who started treatment before new drugs became widely available, especially as part of the frontline treatment. We analyzed 345 symptomatic patients with WM: 130 who initiated treatment before and 215 who started treatment after January 1, 2000. Patients who started treatment in the latter group were older and had more often elevated beta2-microglobulin but the other characteristics were similar between the two groups. Most patients who started treatment before January 1, 2000 were treated upfront with alkylating agent-based regimens and most patients who started treatment after January 1, 2000 received rituximab-based regimens as initial treatment. Objective response (63 and 59%, respectively) and median overall survival, OS, (106.5 months for Group A and is estimated at 94 months for Group B, P = 0.327) were similar. There was also no difference regarding OS or cause specific survival (CSS) in each risk group according to IPSSWM. Our observation may be explained by the indolent course of WM in several patients and by the lack of profound cytoreduction in patients with high-risk disease. Possible differences in the 15- or 20-year survival rate between the two groups may be detected with further follow-up of these patients. Am. J. Hematol. 86:479-483, 2011. (C) 2011 Wiley-Liss, Inc.

Published
2011

33. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

Author

Terpos, Evangelos Katodritou, Eirini Roussou, Maria Pouli, Anastasia Michalis, Eurydiki Delimpasi, Sosana Parcharidou, Agapi Kartasis, Zafiris Zomas, Athanasios Symeonidis, Argiris Viniou, Nora-Athina Anagnostopoulos, Nikolaos and Economopoulos, Theofanis Zervas, Konstantinos Dimopoulos, Meletios A. Greek Myeloma Study Grp Greece

Abstract

Objectives: High serum lactate dehydrogenase (LDH) is associated with features of advanced disease and inferior survival in multiple myeloma. It is however unclear whether LDH adds to the prognostic value of International Staging System (ISS) and whether it retains its prognostic significance in patients who are exposed to novel agent-based therapies. Patients/Methods: To address these issues we analyzed 996 consecutive symptomatic patients who were included in the database of the Greek Myeloma Study Group and received frontline treatment between January 1, 1995 and December 31, 2008. Results: The median overall survival (OS) of all patients was 40 months with a clear improvement in those who started treatment after January 1, 2000 (49 vs. 31 months; P < 0.01). A multivariate model showed that LDH, ISS, performance status, age and platelet counts had an independent prognostic value for OS (P < 0.001 for all parameters). The median OS of patients with high (11% of patients) and normal LDH was 15 vs. 44 months (P < 0.001). High LDH was associated with inferior OS within all ISS groups: 22 vs. 76 months for high and normal LDH groups, respectively, in ISS-1 (P < 0.01); 11 vs. 40 months in ISS-2 (P < 0.001) and 17 vs. 27 months in ISS-3 (P < 0.01). The median OS of high and normal LDH groups among patients who received novel agents was 21 vs. 51 months, respectively (P < 0.001). Conclusions: Lactate dehydrogenase is a readily available and inexpensive variable, which has a major impact on the survival of myeloma patients even when they belong to a low or intermediate ISS subgroup and even when they receive novel agent-based therapies.

Published
2010

34. Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy

Author

Dimopoulos, Meletios A., primary, Terpos, Evangelos, additional, Gavriatopoulou, Maria, additional, Kalapanida, Despoina, additional, Eleutherakis-Papaiakovou, Evangelos, additional, Roussou, Maria, additional, Mparmparoussi, Despoina, additional, Zomas, Athanasios, additional, Gika, Dimitra, additional, Kartasis, Zafiris, additional, Matsouka, Charis, additional, Kostis, Evangelos, additional, Kontogiannis, Sofoklis, additional, Konstantopoulos, Kostas, additional, and Kastritis, Efstathios, additional

Published
2014
Full Text
View/download PDF

35. Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Author

Zomas, Athanasios, primary, Terpos, Evangelos, additional, Katodritou, Eirini, additional, Symeonidis, Argiris, additional, Delimpasi, Sosana, additional, Pouli, Anastasia, additional, Vassilakopoulos, Theodoros P., additional, Michalis, Eurydiki, additional, Giannouli, Stavroula, additional, Kartasis, Zafiris, additional, Christoforidou, Anna, additional, Kokoviadou, Kiriaki, additional, Hatzimichael, Eleftheria, additional, Gika, Dimitra, additional, Megalakaki, Catherine, additional, Papaioannou, Maria, additional, Kyrtsonis, Marie-Christine, additional, Konstantopoulos, Kostas, additional, Dimopoulos, Meletios A., additional, and Kastritis, Efstathios, additional

Published
2014
Full Text
View/download PDF

41. Prognostic value of serum beta(2)-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment

Author

Anagnostopoulos, Athanasios Zervas, Konstantinos Kyrtsonis, Marie Christine Symeonidis, Argyris Gika, Dimitra Bourantas, Konstantinos Zomas, Athanasios Anagnostopoulos, Nikolaos and Pangalis, Gerasimos Dimopoulos, Meletios Athanasios Greek Myeloma Study Grp

Abstract

Purpose: Waldenstrom’s macroglobulinemia (WM) is a lymphoplasmacytoid lymphoma characterized by a relatively indolent course with median survival ranging from 5 years to 10 years in different series. Several clinical and laboratory variables have been associated with inferior survival, such as advanced age, hyperviscosity, presence of cytopenia, and hypoalbuminemia. Recent data indicate that serum beta(2)-microglobulin (beta 2M) might also be significant. The purpose of our study was to assess possible correlations of beta 2M with clinical and laboratory variables and to further evaluate its association with cause-specific and overall survival (OS) of patients with WM requiring treatment. Patients and Methods: We analyzed 124 patients with WM with an available pretreatment value of beta 2M. Median age was 70 years (range, 28-89 years), and median survival was 105 months. Multiple clinical and laboratory parameters were evaluated for their possible correlation with OS. Results: Patients with older age, anemia, thrombocytopenia, hypoalbuminemia, and higher creatinine levels had significantly greater serum beta 2M levels. This variable was associated with impaired cause-specific survival and OS in the whole group of patients and in patients aged 4 mg/dL versus

Published
2006

48. Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group

Author

Kastritis, Efstathios, primary, Katodritou, Eirini, additional, Pouli, Anastasia, additional, Hatzimichael, Eleftheria, additional, Delimpasi, Sosana, additional, Michalis, Eurydiki, additional, Zomas, Athanasios, additional, Kartasis, Zafiris, additional, Parcharidou, Agapi, additional, Gika, Dimitra, additional, Repousis, Panagiotis, additional, Stefanoudaki, Ekaterini, additional, Symeonidis, Argiris, additional, Panayiotidis, Panayiotis, additional, Konstantopoulos, Konstantinos, additional, Terpos, Evangelos, additional, and Dimopoulos, Meletios Athanasios, additional

Published
2011
Full Text
View/download PDF

49. Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia

Author

Tsantes, Argirios E., primary, Nikolopoulos, Georgios K., additional, Tsirigotis, Panagiotis, additional, Zoi, Katerina, additional, Zomas, Athanasios, additional, Kapsimali, Violetta, additional, Kopterides, Petros, additional, Chondropoulos, Spyros, additional, Dervenoulas, John, additional, and Mantzios, Georgios, additional

Published
2011
Full Text
View/download PDF

50. The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

Author

Dimopoulos, Meletios A., primary, Kastritis, Efstathios, additional, Kyrtsonis, Marie-Christine, additional, Meletis, John, additional, Michalis, Eurydiki, additional, Repoussis, Panagiotis, additional, Tsatalas, Konstantinos, additional, Michael, Michael, additional, Pouli, Anastasia, additional, Kartasis, Zafiris, additional, Stefanoudaki, Ekaterini, additional, Voulgarelis, Michael, additional, Delimpasi, Sosana, additional, Katodritou, Eirini, additional, Symeonidis, Argiris, additional, Gavriatopoulou, Maria, additional, Koulieris, Efstathios, additional, Gika, Dimitra, additional, Zomas, Athanasios, additional, Roussou, Paraskevi, additional, Anagnostopoulos, Nikolaos, additional, Economopoulos, Theofanis, additional, Konstantopoulos, Konstantinos, additional, Parcharidou, Agapi, additional, Zervas, Konstantinos, additional, and Terpos, Evangelos, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results